| Literature DB >> 30115869 |
Hao-Bing Yu1,2, Xiao-Li Wang3, Wei-Heng Xu4, Yi-Xin Zhang5, Yi-Sen Qian6, Jian-Peng Zhang7, Xiao-Ling Lu8, Xiao-Yu Liu9.
Abstract
Three new pimarane diterpenes, eutypellenoids A⁻C (1⁻3), together with a known compound, eutypenoid C (4), were isolated from the culture extract of Eutypella sp. D-1 derived from the Arctic region. Compounds 1⁻3 possessed an uncommon tetrahydrofuran-fused pimarane diterpene skeleton. The structures of all compounds were determined by detailed spectroscopic analysis, electronic circular dichroism (ECD) analysis, as well as a comparison with the literature data. Antibacterial, antifungal, and cytotoxic activities of these compounds were evaluated. Compound 2 displayed antibacterial activity against Staphylococcus aureus and Escherichia coli with MIC values of 8 and 8 μg/mL, respectively. Additionally, compound 2 showed antifungal activity against Candidaparapsilosis, Candida albicans, Candida glabrata, and Candida tropicalis with MIC values of 8, 8, 16, and 32 μg/mL, respectively. Furthermore, compound 2 exhibited moderate cytotoxic activity against HCT-116 cell line with IC50 value of 3.7 μM.Entities:
Keywords: Arctic fungus; Eutypella sp.; bioactivity; pimarane diterpene
Mesh:
Substances:
Year: 2018 PMID: 30115869 PMCID: PMC6117666 DOI: 10.3390/md16080284
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of compounds 1–4.
1H and 13C NMR data of compounds 1−3 in CDCl3.
| Position | 1 a | 2 b | 3 b | |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| 1 | 40.6, CH | 2.93, m | 32.3, CH | 3.27, m | 33.0, CH | 3.32, m |
| 2α | 26.0, CH2 | 2.32, m | 26.5, CH2 | 2.35, m | 26.8, CH2 | 2.33, m |
| 2β | 1.70, m | 1.46, m | 1.46, m | |||
| 3 | 74.1, CH | 5.11, t (7.0, 3.5) | 72.7, CH | 5.12, d (1.2) | 72.9, CH | 5.11, d (0.8) |
| 4 | 42.8, C | 40.5, C | 40.5, C | |||
| 5 | 124.7, C | 127.3, C | 126.9, C | |||
| 6 | 145.9, C | 180.3, C | 179.9, C | |||
| 6-OH | 7.17, s | |||||
| 7 | 181.3, C | 142.3, C | 142.4, C | |||
| 7-OH | 6.66, s | 6.52, s | ||||
| 8 | 129.5, C | 122.7, C | 125.8, C | |||
| 9 | 80.9, C | 79.2, C | 77.7, C | |||
| 10 | 76.2, C | 164.8, C | 164.8, C | |||
| 10-OH | 4.41, s | |||||
| 11α | 24.4, CH2 | 1.72, m | 35.8, CH2 | 2.04, m | 35.4, CH2 | 2.04, m |
| 11β | 2.09, m | 1.54, m | 1.41, m | |||
| 12α | 29.7, CH2 | 1.82, m | 26.9, CH2 | 1.57, m | 32.6, CH2 | 1.60, m |
| 12β | 1.64, m | 2.08, m | 1.93, m | |||
| 13 | 39.8, C | 44.9, C | 41.1, C | |||
| 14α | 152.7, CH | 7.11, s | 72.2, CH | 4.68, s | 35.0, CH2 | 2.96, dd (12.8, 2.0) |
| 14β | 2.15, d (12.8) | |||||
| 15 | 142.7, CH | 5.71, dd (17.5, 10.5) | 142.4, CH | 5.72, dd (17.6, 10.8) | 144.0, CH | 5.68, dd (17.6, 10.8) |
| 16a | 114.2, CH2 | 4.86, d (17.5) | 113.7, CH2 | 5.03, d (10.8) | 112.9, CH2 | 4.96, d (10.8) |
| 16b | 5.04, d (10.5) | 5.09, d (17.6) | 5.12, d (17.6) | |||
| 17 | 27.4, CH3 | 1.23, s | 25.2, CH3 | 1.20, s | 30.1, CH3 | 1.15, s |
| 18 | 64.9, CH2 | 4.42, d (14.0) | 65.2, CH2 | 4.35, d (10.8) | 65.3, CH2 | 4.35, d, (10.4) |
| 18 | 4.57, d (14.0) | 4.79, d (10.8) | 4.81, d (10.4) | |||
| 19 | 20.6, CH3 | 1.61, s | 20.9, CH3 | 1.31, s | 20.9, CH3 | 1.31, s |
| 20α | 72.5, CH2 | 4.22, t (18.5, 9.5) | 72.9, CH2 | 4.42, t (8.8) | 71.9, CH2 | 4.36, t (8.0) |
| 20β | 3.47, t (18.0, 9.0) | 3.77, t (8.8) | 3.70, t (8.0) | |||
| 21 | 168.6, C | 169.9, C | 170.0, C | |||
| 22 | 21.1, CH3 | 2.08, s | 21.0, CH3 | 1.99, s | 21.0, CH3 | 1.99, s |
| 23 | 176.6, C | 176.4, C | 176.4, C | |||
| 24 | 34.1, CH | 2.51, m | 34.1, CH | 2.52, m | 34.1, CH | 2.52, m |
| 25 | 18.8, CH3 | 1.13, d (7.0) | 18.8, CH3 | 1.13, d (6.8) | 18.8, CH3 | 1.13, d (6.8) |
| 26 | 18.9, CH3 | 1.14, d (7.0) | 18.9, CH3 | 1.14, d (6.8) | 18.9, CH3 | 1.13, d (6.8) |
a 500 MHz for 1H NMR and 125 MHz for 13C NMR. b 400 MHz for 1H NMR and 100 MHz for 13C NMR.
Figure 2COSY and key HMBC correlations of compounds 1–3.
Figure 3Key NOESY correlations of compounds 1–3.
Figure 4Experimental and calculated ECD spectra of compound 1.
Figure 5Experimental and calculated ECD spectra of compound 2.
Figure 6Experimental and calculated ECD spectra of compound 3.
Antibacterial activities of compounds 1–4.
| Compound | MIC (μg/mL) | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
| 1 | 32 | 32 | 64 | 64 | 32 | 64 | 64 |
| 2 | 8 | 8 | 32 | 32 | 32 | 32 | 32 |
| 3 | 32 | 32 | 32 | 64 | 64 | 64 | 64 |
| 4 | 32 | 64 | 64 | 64 | 64 | 64 | 64 |
| Chloromycetin | 4 | 4 | 2 | 1 | 1 | 1 | 1 |
Antifungal activities of compounds 1–4.
| Compound | MIC (μg/mL) | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1 | >64 | >64 | >64 | >64 | >64 | >64 |
| 2 | 8 | 8 | 16 | >64 | >64 | 32 |
| 3 | >64 | >64 | 64 | >64 | >64 | >64 |
| 4 | >64 | >64 | 64 | >64 | >64 | >64 |
| Fluconazole | 0.50 | 2 | 0.50 | 1 | 2 | 0.25 |
| Posaconazole | 0.50 | 0.12 | 0.50 | 0.02 | 1 | 0.02 |
| Voriconazole | 0.02 | 0.03 | 0.02 | 0.02 | 0.06 | 0.02 |
Cytotoxic activities of compounds 1–4.
| Compound | IC50 (μM) | ||||
|---|---|---|---|---|---|
| HeLa | MCF-7 | HCT-116 | K562 | SW1990 | |
| 1 | 24.4 | 26.2 | 20.7 | 30.9 | 23.6 |
| 2 | 15.1 | 20.3 | 3.7 | 23.3 | 33.6 |
| 3 | 41.5 | 36.5 | 31.6 | >50 | >50 |
| 4 | 46.5 | 40.1 | 27.1 | 32.1 | >50 |
| Cisplatin | 0.5 | 4.5 | 2.7 | 2.7 | 1.0 |